Neuraxis (NRXS) FCF Margin (2022 - 2025)

Neuraxis (NRXS) posted FCF Margin of 200.39% for Q4 2025, down 13.9% sequentially from 175.93% in Q3 2025, and up 3059.0% YoY from 6.34% in Q4 2024.

Neuraxis (NRXS) FCF Margin (2022 - 2025) Analysis & Trends

Neuraxis has reported FCF Margin for 4 years, with the latest figure at 200.39% in Q4 2025.

Quarterly FCF Margin rose 3059.0% year-over-year to 200.39% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 181.1% (up 4698.0% YoY) and the FY2025 annual result came in at 181.1%, up 4698.0% from the prior year.
FCF Margin eased to 200.39% in Q4 2025 per NRXS's latest filing, from 175.93% in the prior quarter.
Over five years, FCF Margin peaked at 33.33% in Q4 2022 and troughed at 590.41% in Q3 2023.
A 4-year average of 220.1% and a median of 190.72% in 2025 frame the typical range for FCF Margin.
The sharpest annual moves came in 2023 and 2024: FCF Margin slumped 46447 bps in 2023, then surged 38082 bps in 2024.
Over 4 years, FCF Margin stood at 33.33% in 2022, then slumped by 1394 bps to 497.8% in 2023, then soared by 54 bps to 230.98% in 2024, then increased by 13 bps to 200.39% in 2025.
According to Business Quant data, FCF Margin over the past three periods registered 200.39%, 175.93%, and 164.95% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	138.41 Bn	130.56 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.12 Bn	78.12 Bn	3.93 Bn	13.35%
3	Argenx Se	64.41 Bn	59.23 Bn	1.37 Bn	-
4	Moderna	57.56 Bn	52.43 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.06 Bn	36.96 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.95 Bn	27.65 Bn	992.69 Mn	22.62%
7	BioNTech SE	27.48 Bn	9.09 Bn	668.28 Mn	41.07%
8	Insmed	27.31 Bn	26.15 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.04 Bn	26.20 Bn	-	70.82%
10	Neuraxis	78.80 Mn	70.48 Mn	-	-

Download Data